Is hypertriglyceridemia a key detrimental factor or associative triggering factor for cardiovascular abnormalities?

Balakumar, Pitchai; Babbar, Lalita; Kalra, Sanjeev; Mahadevan, Nanjaian; Sritharan, Seetharaman; Krishan, Pawan

doi:10.4103/0975-8453.107127

Cited by 1 publication

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HTG itself can be divided into primary and secondary types, but a molecular basis for primary HTG has been found in less than 5% of cases and for secondary cases, no genetic susceptibility component that is reproducible. (4,5) Primary HTG is mainly due to genetic predisposition. Chylomicrons normally are cleared rapidly from plasma by LPL with apo-C-II as a cofactor.…”

Section: Hypertriglyceridemiamentioning

confidence: 99%

The Association between Cardiovascular Risk and Elevated Triglycerides

Sargowo

Handayani

2017

Indones Biomed J

View full text Add to dashboard Cite

BACKGROUND: The association between elevated triglycerides and cardiovascular risk has been extensively studied. The elevated level of triglycerides occurs through abnormalities in hepatic very low-density lipoprotein (VLDL) production and intestinal chylomicron synthesis, dysfunctional lipoprotein lipase (LPL)-mediated lipolysis or impaired remnant clearance.CONTENT: Hypertriglyceridemia (HTG) commonly leads to a reduction in high-density lipoprotein (HDL) and increase in atherogenic small dense low-density lipoprotein (LDL) cholesterol, called the atherogenic dyslipidemia (AD). Triglycerides may also stimulate atherogenesis by mechanisms, such excessive release of free fatty acids, and production of pro-inflammatory cytokines, fibrinogen, coagulation factors and impairment of fibrinolysis. Genetic studies strongly support hypertriglyceridemia (HTG) and high concentration of triglyceride-rich lipoprotein (TRL) as causal risk factors for cardiovascular disease. Therefore, lipid management is crucial in reducing cardiovascular risk. Combination of lipid lowering drug therapy may be needed to achieve both LDL and non-HDL cholesterols treatment goal for cardiovascular disease prevention in patients with elevated triglyceride levels, particularly those with triglyceride ≥500 mg/dL.SUMMARY: LDL and non-HDL cholesterol can be a promising target therapy in HTG. Additional clinical outcomes data are needed to provide a more evidence-based rationale for clinical lipid management of hypertriglyceridemic patients.KEYWORDS: hypertriglyceridemia, non-HDL cholesterol, dyslipidemia, CV risk

show abstract

Section: Hypertriglyceridemiamentioning

confidence: 99%